Literature DB >> 19092656

Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation.

Vance G Nielsen1, James K Kirklin, William L Holman, Brad L Steenwyk.   

Abstract

Warfarin therapy has served as the backbone of chronic anticoagulation therapy for decades to prevent thrombotic morbidity secondary to blood-biomaterial interfaces. Unfortunately, thrombotic and bleeding complications are observed despite maintenance of therapeutic international normalized ratio (INR) values. We proposed to define the effects of warfarin therapy on thrombus growth and disintegration following contact pathway protein or tissue factor (TF) initiation. Normal subject or patient plasma with INR values between 1.8 and 9.6 were exposed to TF or celite and tissue-type plasminogen activator (tPA). Thrombus growth/disintegration kinetics were determined by changes in resistance over time with the clot lifespan model (CSLM), a thrombelastographic-based methodology. Data were collected until clot lysis time was observed. Linear relationships of the difference between the CLSM parameter values obtained from paired celite and TF-activated samples and corresponding INR value were determined and reported as r. The time to clot initiation was progressively prolonged with increasing INR values in all samples, and speed of clot formation, clot strength, and time to onset of fibrinolysis decreased as INR increased. Throughout the range of INR values tested, contact activation resulted in faster growing, stronger, and longer lived thrombi when compared with matched TF-activated plasma samples. Only the time to maximum rate of lysis was correlated with INR (r=0.36, p=0.005). INR values have little correlation with the difference between contact protein and TF-activated coagulation/fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19092656     DOI: 10.1097/MAT.0b013e318190c1a9

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  2 in total

1.  Susceptibility Vessel Sign and Cardioembolic Etiology in the THRACE Trial.

Authors:  Romain Bourcier; Imad Derraz; Béatrice Delasalle; Marine Beaumont; Sebastien Soize; Laurence Legrand; Hubert Desal; Serge Bracard; Olivier Naggara; Catherine Oppenheim
Journal:  Clin Neuroradiol       Date:  2018-06-12       Impact factor: 3.649

2.  Validation of overestimation ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI.

Authors:  Romain Bourcier; Laurence Legrand; Sébastien Soize; Julien Labreuche; Marine Beaumont; Hubert Desal; Imad Derraz; Serge Bracard; Catherine Oppenheim; Olivier Naggara
Journal:  Eur Radiol       Date:  2018-11-12       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.